Kymera Stock: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon (KYMR)
· seekingalpha.com
Kymera Therapeutics (KYMR) eyes pivotal BROADEN2 Phase 2b data for KT-621, a STAT6 degrader in atopic dermatitis—upside vs. Dupixent. See more here.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...